Several Pakistani pharmaceutical companies have started domestic production of generic versions of Ozempic/Wegovy (Semaglutide) and Mounjaro/Zeptide (Tirzepatide). Priced significantly lower than the branded imports, these domestically manufactured generic drugs will increase Pakistanis' access and affordability to address the obesity crisis in the country, resulting in lower disease burdens and improved life quality and longer life expectancy. Obesity causes diabetes, hypertension, heart disease and other non-communicable diseases (NCD) which are now among the leading causes of death in Pakistan.
 |
| Pakistan Pharmaceutical Companies |
BF Biosciences, Ferozsons, Getz Pharma and GD Searle Co are among the leading pharma producers of both injectable and pill versions of the GLP-1 and GIP drugs in Pakistan. Over the last few years, these drugs have revolutionized treatment of diabetes and obesity. Now, Pakistani pharmaceutical companies have begun manufacturing biosimilar versions of these therapies locally, marking a major milestone in access and affordability. Biosimilars are biologic medicines developed to match the safety, efficacy, and quality of their international counterparts, approved only after rigorous regulatory evaluation, according to Pakistani media reports.
 |
| Obesity Risk Among Men. Source: World Obesity Atlas |
The obesity crisis has become a global health emergency with over a billion people living with obesity in the world, creating global opportunities for weight-loss drugmakers. Rapidly rising rates of obesity in adults and children are being blamed on factors like processed foods, sedentary lifestyles, and stress, leading to serious conditions like diabetes, heart disease, certain cancers, and huge healthcare costs, requiring multifaceted solutions including policy changes, better nutrition, and integrated healthcare.
 |
| Obesity Risk Among Women. Source: World Obesity Atlas |
Pakistani drugmakers are planning to export these weight-loss and diabetes drugs in the near future. Over a dozen pharma companies are upgrading factories with a total investment of more than $500 million to ensure their medications and factories are compliant with overseas regulations, said Javed Ghulam Mohammad, chief executive officer at Martin Dow Group. His company is a member of the Pakistan Pharmaceutical Manufacturers Association, which is backing the effort. The sector’s push comes as the nation looks to increase overall exports to lift the economy.
The country's drug exports have increased the most in two decades in the fiscal year ending in June, 2025, growing 34% to $457 million, according to the association. Pharmaceutical shipments have the potential to reach $5 billion in eight years if the overseas push is successful, Mohammad said. That would make pharmaceuticals among Pakistan’s largest product exports, according to Bloomberg.
Related Links:
Haq's Musings
South Asia Investor Review
Pakistanis Happier Than Neighbors
Tipping Point: Pakistan Middle Class Grows to 55% of the Population
High Disease Burdens in India and Pakistan
World Bank: Pakistan is 88% Urbanized
Agriculture Sector in Pakistan
BMI: America Significantly Outweighs Asia
Health Risks Rise With Bunge Pakistan
Pakistan Rising or Failing: Reality vs Perception
Pakistan's Trillion Dollar Economy Among top 25
Pakistan Pharma Among World's Fastest Growing
1 comment:
Oh no, once more you have lumped India with sub- Saharan Africa, this is going too irk Vineeth.
How dare you don't follow the party line set by GoI.
G. Ali
Post a Comment